Antiphospholipid syndrome (APS) is a thrombo-inflammatory disease propelled by
circulating autoantibodies that recognize cell surface phospholipids and phospholipid …

Cerebral venous thrombosis accounts for 0.5% to 3% of all strokes. The most vulnerable
populations include young individuals, women of reproductive age, and patients with a …

Background The efficacy and safety of direct oral anticoagulants (DOACs) for patients with
thrombotic antiphospholipid syndrome remain controversial. Objectives The authors …

AIM: The “2024 Guideline for the Primary Prevention of Stroke” replaces the 2014
“Guidelines for the Primary Prevention of Stroke.” This updated guideline is intended to be a …

Although the knowledge of APS pathogenesis has grown in recent years, the management
principles and strategies are largely unchanged. There is an unmet need for evaluating …

Review of the guideline followed the standard BSH guidelines procedure. Following review
of the draft guideline by the BSH Haemostasis and Thrombosis Task Force and the BSH …

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by the
persistent positivity of antiphospholipid antibodies (aPLA) together with thrombosis or …

Background The optimal strategy for diagnosis and antithrombotic treatment of patients with
antiphospholipid syndrome (APS)–associated acute ischemic stroke (AIS), transient …

Anticoagulant drugs that are currently used to prevent and/or treat thrombosis have some
limitations that hinder their ability to meet specific clinical requirements. While these drugs …

Antiphospholipid syndrome (APS) is characterized by thrombosis (which may be venous,
arterial, or microvascular) and/or pregnancy morbidity in association with persistently …